KYMR
$58.18
Revenue | $11.48Mn |
Net Profits | $-76.61Mn |
Net Profit Margins | -667.6% |
Kymera Therapeutics Inc’s revenue fell -55.26% since last year same period to $11.48Mn in the Q2 2025. On a quarterly growth basis, Kymera Therapeutics Inc has generated -48.07% fall in its revenue since last 3-months.
Kymera Therapeutics Inc’s net profit fell -82.15% since last year same period to $-76.61Mn in the Q2 2025. On a quarterly growth basis, Kymera Therapeutics Inc has generated -16.82% fall in its net profits since last 3-months.
Kymera Therapeutics Inc’s net profit margin fell -307.11% since last year same period to -667.6% in the Q2 2025. On a quarterly growth basis, Kymera Therapeutics Inc has generated -124.97% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Current Year | -0.86 |
Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.86 - a -3.77% fall from last quarter’s estimates.
Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.86.
Earning Per Share (EPS) | -0.95 |
Kymera Therapeutics Inc’s earning per share (EPS) fell -63.79% since last year same period to -0.95 in the Q2 2025. This indicates that the Kymera Therapeutics Inc has generated -63.79% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-05-09 | -0.73 | -0.82 | -12.33% |
2025-08-11 | -0.83 | -0.95 | -14.46% |